RCT on NPWT for Incisions Following Major Lower-limb Amputation to Reduce Surgical Site Infection
NCT ID: NCT03144726
Last Updated: 2017-12-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
290 participants
INTERVENTIONAL
2018-03-31
2020-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Postoperative wound complications, such as infection, dehiscence, and formation of haematoma or seroma, are common complications of surgical procedures; particularly among patients with risk factors such as obesity and diabetes. Wound complications may delay recovery, increase patient discomfort and reduce overall quality of life. Increased healthcare costs may be incurred due to prolonged inpatient stay, repeat surgery and the need for increased follow-up.
Wounds that are secondary to amputation are reported in 13-40% of cases and are one of the most challenging types of lower extremity wounds to heal. These patients often have compromised healing capacity. Kayssi et al studied Canadian readmission rates, early (\<30 days) and late (30-365) readmissions were attributed to stump complications in 13% and 10% of patients respectively.
Wound complications in major limb amputation frequently result in the need for further major surgery in a group of patients with significant co-morbidity and enhanced operative risk. 1, 3, and 5 year reamputation rates for diabetics who have had major amputations are 4.7%, 11.8%, and 13.3% respectively. Henry et al suggested that undergoing multiple amputation revisions may indicate aggressive measures to treat critical limb ischemia or chronic infection that precede conversion to a more proximal amputation. Kono et al studied the incidence and risk factors for reamputation after forefoot amputation. They found that 16/116 (14%) patients developed postoperative infection, and 10 of these required reamputation (62.5%). Five of the ten reamputations occurred within 30 days after the patients developed postoperative infections.
In addition to the morbidity from infection there is also an increased rate of phantom pain as well as a delay to mobilisation with prosthesis. Minimizing postoperative infections would likely have improvements in clinical outcomes, quality of life, and utilization of resources. Currently, all patients are given prophylactic broad spectrum antibiotics to reduce the incidence of wound infection. Sadat et al investigated whether a prolonged 5 day course of antibiotics wound reduce stump infections, their results were positive however this treatment is associated with the increased risk of antimicrobial resistance and c. difficile infection.
Negative-pressure wound therapy (NPWT) has traditionally been used for the treatment of open wounds. In recent years, the indication for NPWT has been extended to include treatment of closed surgical incisions. Armstrong et al conducted a randomized controlled trial to determine whether NPWT delivered by the VAC system was clinically efficacious in treating amputation wounds of the diabetic foot to improve the proportion of wounds with complete closure. Treatment with NPWT resulted in a higher proportion of wounds that healed, faster healing rates, and fewer re-amputations than with standard treatment. No randomized controlled trials have been performed to assess NPWT and infection rates after major lower limb amputation.
There is a paucity of scientific literature reporting outcomes following major amputation in patients with critical limb ischemia, particularly with regards to wound problems and infection. The purpose of this study is to provide Level I evidence on whether negative pressure wound therapy is an effective strategy to significantly reduce postoperative infections after major lower extremity amputation, thereby reducing patient morbidity and mortality from this procedure.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Negative pressure wound therapy
A vacuum assisted closure device will be applied in this arm
Negative pressure wound therapy
Negative pressure wound therapy is a commonly utilized tool in the hospital setting and will be applied to amputations in our study to determine the effect on surgical site infections
Standard dressing
Standard dressing will be applied to this arm
Standard dressing
A standard dressing will be applied to the amputations in this arm of the study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Negative pressure wound therapy
Negative pressure wound therapy is a commonly utilized tool in the hospital setting and will be applied to amputations in our study to determine the effect on surgical site infections
Standard dressing
A standard dressing will be applied to the amputations in this arm of the study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ability to read and write English to undergo informed consent
Exclusion Criteria
* wounds that are not closed primarily
* existing infection
* patient is anticipated to not follow-up
* inability to read and write English
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
London Health Sciences Centre
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adam Power
Physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adam Power, MD
Role: PRINCIPAL_INVESTIGATOR
London Health Sciences Centre
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REB 109128
Identifier Type: -
Identifier Source: org_study_id